Retension Pharmaceuticals, Inc.

Overview

Compare with another stock.

• TickerRTSN on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersFalls Church, United States²
• Incorporated inDE³
• Business addressC/O Redux Therapeutics, Llc, 902 Turkey Run Road, Mclean, Va 22101³
• Filer category, Emerging growth company³
• Legal formCorporation²
• LEI529900QBUEUWO67CZD11²
• StatusActive²
• LEI statusIssued and current²
• Registered addressc/o THE CORPORATION TRUST COMPANY,CORPORATION TRUST CENTER 1209 ORANGE STREET, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 7589570²

See how the biggest companies compare on our leaderboards

Corporate structure

Retension Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorEric Keller named May 15, 2024 to May 6, 2025⁴
• DirectorDonald Olds named May 15, 2024 to May 6, 2025⁴
• DirectorMichael Berendt named May 15, 2024 to May 6, 2025⁴

Timeline

1. Oct 13, 20268-K Bylaws or fiscal year changed⁵
2. Jul 26, 2023Founded Retension Pharmaceuticals, Inc. is founded²

Filings

38 filings to the SEC since October 2021: 1 major events, 19 insider forms, 2 large holders, 3 private raises, 13 other. The latest 20:

1. Oct 15, 2026SCHEDULE 13G EDGAR
2. Oct 14, 2026SCHEDULE 13D EDGAR
3. Oct 13, 20264 OWNERSHIP DOCUMENT EDGAR
4. Oct 13, 20264 EDGAR
5. Oct 13, 20264 EDGAR
6. Oct 13, 20264 EDGAR
7. Oct 13, 20264 EDGAR
8. Oct 13, 20264 EDGAR
9. Oct 13, 20264 EDGAR
10. Oct 13, 20263 EDGAR
11. Oct 13, 2026S-8 REGISTRATION STATEMENT EDGAR
12. Oct 13, 20268-K CURRENT REPORT EDGAR
13. Oct 9, 2026424B4 PROSPECTUS EDGAR
14. Oct 8, 2026EFFECT EDGAR
15. Oct 8, 2026CERT EDGAR
16. Oct 8, 20264 EDGAR
17. Oct 8, 20264 EDGAR
18. Oct 8, 20264 EDGAR
19. Oct 8, 2026S-1MEF REGISTRATION STATEMENT EDGAR
20. Oct 8, 20263 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Laurence W. LyttonSCHEDULE 13G, 1 filing Oct 15, 2026⁶
• Eric L. KellerSCHEDULE 13D, 1 filing Oct 14, 2026⁷

Money raised

Private offerings the company reported to the SEC on Form D.

1. Apr 22, 2025Raised $12.3 million in a private offering of equity Form D: $20 million offered in all Form D
2. Nov 21, 2023Raised $10.1 million in a private offering of equity Form D: $11 million offered in all Form D

SEC filer profile

How Retension Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARRetension Pharmaceuticals, Inc.¹
• CIK0002002988
• Employer ID (EIN)93-2592788¹
• Filer status<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressC/O Redux Therapeutics, Llc, 902 Turkey Run Road, Mclean, VA 22101¹
• Phone(703) 624-2024¹
• On EDGAR sinceDec 5, 2023¹
• Filings38 in all: 4 (10), 3 (9), DRS/A (3), D (2), S-1/A (2), 424B4 (1), 8-A12B (1), 8-K (1)¹
  All 17 form types

  CERT (1), D/A (1), DRS (1), EFFECT (1), S-1 (1), S-1MEF (1), S-8 (1), SCHEDULE 13D (1), SCHEDULE 13G (1)

• Latest filingsLatest 8-K (8-K) Oct 13, 2026